Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ionis Pharmaceuticals, Inc. (IONS : NSDQ)
 
 • Company Description   
Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

Number of Employees: 1,402

 
 • Price / Volume Information   
Yesterday's Closing Price: $81.15 Daily Weekly Monthly
20 Day Moving Average: 2,046,139 shares
Shares Outstanding: 165.19 (millions)
Market Capitalization: $13,405.33 (millions)
Beta: 0.31
52 Week High: $86.74
52 Week Low: $23.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.84% -0.98%
12 Week -0.65% -0.77%
Year To Date 2.58% 2.08%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2855 GAZELLE COURT
-
CARLSBAD,CA 92010
USA
ph: 760-931-9200
fax: 760-603-2700
ir@ionis.com https://ionis.com
 
 • General Corporate Information   
Officers
Brett P. Monia - Chief Executive Officer
Joseph Loscalzo - Chairman of the Board
Elizabeth L. Hougen - Executive Vice President; Finance and Chief Financ
Allene M. Diaz - Director
Joan E. Herman - Director

Peer Information
Ionis Pharmaceuticals, Inc. (GSAC)
Ionis Pharmaceuticals, Inc. (CASIF)
Ionis Pharmaceuticals, Inc. (ALCD.)
Ionis Pharmaceuticals, Inc. (OMNN)
Ionis Pharmaceuticals, Inc. (CGPI.)
Ionis Pharmaceuticals, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 462222100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 04/29/26
Share - Related Items
Shares Outstanding: 165.19
Most Recent Split Date: (:1)
Beta: 0.31
Market Capitalization: $13,405.33 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/29/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 26.88
Price/Cash Flow: -
Price / Sales: 14.20
EPS Growth
vs. Year Ago Period: -113.64%
vs. Previous Quarter: -76.25%
Sales Growth
vs. Year Ago Period: -10.57%
vs. Previous Quarter: 29.30%
ROE
12/31/25 - -68.82
09/30/25 - -44.26
06/30/25 - -45.29
ROA
12/31/25 - -12.34
09/30/25 - -8.65
06/30/25 - -8.99
Current Ratio
12/31/25 - 3.83
09/30/25 - 2.79
06/30/25 - 2.87
Quick Ratio
12/31/25 - 3.81
09/30/25 - 2.78
06/30/25 - 2.86
Operating Margin
12/31/25 - -40.36
09/30/25 - -26.45
06/30/25 - -28.25
Net Margin
12/31/25 - -40.36
09/30/25 - -26.45
06/30/25 - -28.25
Pre-Tax Margin
12/31/25 - -40.22
09/30/25 - -26.73
06/30/25 - -29.04
Book Value
12/31/25 - 3.02
09/30/25 - 3.82
06/30/25 - 3.96
Inventory Turnover
12/31/25 - 1.57
09/30/25 - 1.10
06/30/25 - 0.69
Debt-to-Equity
12/31/25 - 2.76
09/30/25 - 0.96
06/30/25 - 0.99
Debt-to-Capital
12/31/25 - 73.37
09/30/25 - 49.09
06/30/25 - 49.75
 

Powered by Zacks Investment Research ©